Inhibikase Therapeutics, Inc. (IKT) Depreciation USD 2022 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from 2022 to 2024.
  • Inhibikase Therapeutics, Inc. Depreciation for the quarter ending March 31, 2024 was $6.57 K, a 30.2% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Depreciation for the twelve months ending March 31, 2024 was $179 K, a 1421% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2023 was $177 K, a 2539% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2022 was $6.72 K.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $179 K $6.57 K +$1.53 K +30.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $177 K $6.58 K +$1.54 K +30.6% Oct 1, 2023 Dec 31, 2023 10-Q 2024-05-15
Q3 2023 $176 K $6.57 K +$4.89 K +291% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $171 K $159 K +$159 K Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $11.8 K $5.04 K +$5.04 K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $6.72 K $5.04 K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $1.68 K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.